author_facet Epstein, Richard J.
Leung, Thomas W.
Epstein, Richard J.
Leung, Thomas W.
author Epstein, Richard J.
Leung, Thomas W.
spellingShingle Epstein, Richard J.
Leung, Thomas W.
Clinical Cancer Research
Reversing Hepatocellular Carcinoma Progression by Using Networked Biological Therapies
Cancer Research
Oncology
author_sort epstein, richard j.
spelling Epstein, Richard J. Leung, Thomas W. 1078-0432 1557-3265 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/1078-0432.ccr-06-1619 <jats:title>Abstract</jats:title> <jats:p>The liver is distinguished from other tissues by (a) its detoxifying function, (b) its resistance to apoptosis, and (c) its regenerative response to damage. Hepatocellular carcinoma arises when chronic insults, such as hepatitis or iron overload, constitutively activate this regenerative program. Here, we propose that the proliferative response of the liver to damage underlies the resistance of hepatocellular carcinoma to cytotoxic therapy, and that hepatocellular carcinoma growth should therefore be more readily controlled by using a networked combination of noncytotoxic interventions to interrupt the damage-inducible regenerative pathway. To this end, hepatocellular carcinoma boasts a wealth of potential drug targets, including viral replication, the antiapoptotic immunosuppressant α-fetoprotein, hepatic iron overload, inflammatory signaling, extracellular proteases, and growth factors. By blocking these positive feedback loops in parallel, and so returning the host environment to a more normal state, epigenetic repression of tumor-suppressor gene function may be reversed and tumor dormancy restored. Noncytotoxic maneuvers that short circuit damage resistance loops may thus represent an indirect form of gene therapy meriting incorporation into hepatocellular carcinoma clinical trials.</jats:p> Reversing Hepatocellular Carcinoma Progression by Using Networked Biological Therapies Clinical Cancer Research
doi_str_mv 10.1158/1078-0432.ccr-06-1619
facet_avail Online
Free
finc_class_facet Medizin
format ElectronicArticle
fullrecord blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xMDc4LTA0MzIuY2NyLTA2LTE2MTk
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xMDc4LTA0MzIuY2NyLTA2LTE2MTk
institution DE-Zwi2
DE-D161
DE-Gla1
DE-Zi4
DE-15
DE-Pl11
DE-Rs1
DE-105
DE-14
DE-Ch1
DE-L229
DE-D275
DE-Bn3
DE-Brt1
imprint American Association for Cancer Research (AACR), 2007
imprint_str_mv American Association for Cancer Research (AACR), 2007
issn 1078-0432
1557-3265
issn_str_mv 1078-0432
1557-3265
language English
mega_collection American Association for Cancer Research (AACR) (CrossRef)
match_str epstein2007reversinghepatocellularcarcinomaprogressionbyusingnetworkedbiologicaltherapies
publishDateSort 2007
publisher American Association for Cancer Research (AACR)
recordtype ai
record_format ai
series Clinical Cancer Research
source_id 49
title Reversing Hepatocellular Carcinoma Progression by Using Networked Biological Therapies
title_unstemmed Reversing Hepatocellular Carcinoma Progression by Using Networked Biological Therapies
title_full Reversing Hepatocellular Carcinoma Progression by Using Networked Biological Therapies
title_fullStr Reversing Hepatocellular Carcinoma Progression by Using Networked Biological Therapies
title_full_unstemmed Reversing Hepatocellular Carcinoma Progression by Using Networked Biological Therapies
title_short Reversing Hepatocellular Carcinoma Progression by Using Networked Biological Therapies
title_sort reversing hepatocellular carcinoma progression by using networked biological therapies
topic Cancer Research
Oncology
url http://dx.doi.org/10.1158/1078-0432.ccr-06-1619
publishDate 2007
physical 11-17
description <jats:title>Abstract</jats:title> <jats:p>The liver is distinguished from other tissues by (a) its detoxifying function, (b) its resistance to apoptosis, and (c) its regenerative response to damage. Hepatocellular carcinoma arises when chronic insults, such as hepatitis or iron overload, constitutively activate this regenerative program. Here, we propose that the proliferative response of the liver to damage underlies the resistance of hepatocellular carcinoma to cytotoxic therapy, and that hepatocellular carcinoma growth should therefore be more readily controlled by using a networked combination of noncytotoxic interventions to interrupt the damage-inducible regenerative pathway. To this end, hepatocellular carcinoma boasts a wealth of potential drug targets, including viral replication, the antiapoptotic immunosuppressant α-fetoprotein, hepatic iron overload, inflammatory signaling, extracellular proteases, and growth factors. By blocking these positive feedback loops in parallel, and so returning the host environment to a more normal state, epigenetic repression of tumor-suppressor gene function may be reversed and tumor dormancy restored. Noncytotoxic maneuvers that short circuit damage resistance loops may thus represent an indirect form of gene therapy meriting incorporation into hepatocellular carcinoma clinical trials.</jats:p>
container_issue 1
container_start_page 11
container_title Clinical Cancer Research
container_volume 13
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
_version_ 1792338873697697799
geogr_code not assigned
last_indexed 2024-03-01T15:39:09.531Z
geogr_code_person not assigned
openURL url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Reversing+Hepatocellular+Carcinoma+Progression+by+Using+Networked+Biological+Therapies&rft.date=2007-01-01&genre=article&issn=1557-3265&volume=13&issue=1&spage=11&epage=17&pages=11-17&jtitle=Clinical+Cancer+Research&atitle=Reversing+Hepatocellular+Carcinoma+Progression+by+Using+Networked+Biological+Therapies&aulast=Leung&aufirst=Thomas+W.&rft_id=info%3Adoi%2F10.1158%2F1078-0432.ccr-06-1619&rft.language%5B0%5D=eng
SOLR
_version_ 1792338873697697799
author Epstein, Richard J., Leung, Thomas W.
author_facet Epstein, Richard J., Leung, Thomas W., Epstein, Richard J., Leung, Thomas W.
author_sort epstein, richard j.
container_issue 1
container_start_page 11
container_title Clinical Cancer Research
container_volume 13
description <jats:title>Abstract</jats:title> <jats:p>The liver is distinguished from other tissues by (a) its detoxifying function, (b) its resistance to apoptosis, and (c) its regenerative response to damage. Hepatocellular carcinoma arises when chronic insults, such as hepatitis or iron overload, constitutively activate this regenerative program. Here, we propose that the proliferative response of the liver to damage underlies the resistance of hepatocellular carcinoma to cytotoxic therapy, and that hepatocellular carcinoma growth should therefore be more readily controlled by using a networked combination of noncytotoxic interventions to interrupt the damage-inducible regenerative pathway. To this end, hepatocellular carcinoma boasts a wealth of potential drug targets, including viral replication, the antiapoptotic immunosuppressant α-fetoprotein, hepatic iron overload, inflammatory signaling, extracellular proteases, and growth factors. By blocking these positive feedback loops in parallel, and so returning the host environment to a more normal state, epigenetic repression of tumor-suppressor gene function may be reversed and tumor dormancy restored. Noncytotoxic maneuvers that short circuit damage resistance loops may thus represent an indirect form of gene therapy meriting incorporation into hepatocellular carcinoma clinical trials.</jats:p>
doi_str_mv 10.1158/1078-0432.ccr-06-1619
facet_avail Online, Free
finc_class_facet Medizin
format ElectronicArticle
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
geogr_code not assigned
geogr_code_person not assigned
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xMDc4LTA0MzIuY2NyLTA2LTE2MTk
imprint American Association for Cancer Research (AACR), 2007
imprint_str_mv American Association for Cancer Research (AACR), 2007
institution DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1
issn 1078-0432, 1557-3265
issn_str_mv 1078-0432, 1557-3265
language English
last_indexed 2024-03-01T15:39:09.531Z
match_str epstein2007reversinghepatocellularcarcinomaprogressionbyusingnetworkedbiologicaltherapies
mega_collection American Association for Cancer Research (AACR) (CrossRef)
physical 11-17
publishDate 2007
publishDateSort 2007
publisher American Association for Cancer Research (AACR)
record_format ai
recordtype ai
series Clinical Cancer Research
source_id 49
spelling Epstein, Richard J. Leung, Thomas W. 1078-0432 1557-3265 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/1078-0432.ccr-06-1619 <jats:title>Abstract</jats:title> <jats:p>The liver is distinguished from other tissues by (a) its detoxifying function, (b) its resistance to apoptosis, and (c) its regenerative response to damage. Hepatocellular carcinoma arises when chronic insults, such as hepatitis or iron overload, constitutively activate this regenerative program. Here, we propose that the proliferative response of the liver to damage underlies the resistance of hepatocellular carcinoma to cytotoxic therapy, and that hepatocellular carcinoma growth should therefore be more readily controlled by using a networked combination of noncytotoxic interventions to interrupt the damage-inducible regenerative pathway. To this end, hepatocellular carcinoma boasts a wealth of potential drug targets, including viral replication, the antiapoptotic immunosuppressant α-fetoprotein, hepatic iron overload, inflammatory signaling, extracellular proteases, and growth factors. By blocking these positive feedback loops in parallel, and so returning the host environment to a more normal state, epigenetic repression of tumor-suppressor gene function may be reversed and tumor dormancy restored. Noncytotoxic maneuvers that short circuit damage resistance loops may thus represent an indirect form of gene therapy meriting incorporation into hepatocellular carcinoma clinical trials.</jats:p> Reversing Hepatocellular Carcinoma Progression by Using Networked Biological Therapies Clinical Cancer Research
spellingShingle Epstein, Richard J., Leung, Thomas W., Clinical Cancer Research, Reversing Hepatocellular Carcinoma Progression by Using Networked Biological Therapies, Cancer Research, Oncology
title Reversing Hepatocellular Carcinoma Progression by Using Networked Biological Therapies
title_full Reversing Hepatocellular Carcinoma Progression by Using Networked Biological Therapies
title_fullStr Reversing Hepatocellular Carcinoma Progression by Using Networked Biological Therapies
title_full_unstemmed Reversing Hepatocellular Carcinoma Progression by Using Networked Biological Therapies
title_short Reversing Hepatocellular Carcinoma Progression by Using Networked Biological Therapies
title_sort reversing hepatocellular carcinoma progression by using networked biological therapies
title_unstemmed Reversing Hepatocellular Carcinoma Progression by Using Networked Biological Therapies
topic Cancer Research, Oncology
url http://dx.doi.org/10.1158/1078-0432.ccr-06-1619